A prospective study examining the effect of dienogest treatment on endometrioma size and symptoms

Abstract

Objective

We aimed to determine the effect of dienogest on cyst volume, symptoms, and quality of life in patients with endometrioma.

Method

This prospective cohort study included 37 patients diagnosed with endometrioma and planned for medical treatment. Subjects were treated with a 3-month oral dose of dienogest 2 mg/day. Pre-treatment and post-treatment endometriosis measurements were assessed via 3D ultrasonography, pain symptoms via 100-mm visual analog scale (VAS), and quality of life via Short Form-36.

Results

The mean age of the patients was 36.0 ± 6.6 years. The mean endometrioma volume was significantly reduced by 31% after treatment (26.7 ± 19.7 mm³) compared to the pre-treatment volume (17.4 ± 11.2 mm³, p < .001). Post-treatment VAS scores of dysmenorrhea, dyspareunia, and chronic pelvic pain VAS values were significantly decreased by 35.5% (p < .001), 37.5% (p < .001), and 38.5% (p < .001), respectively. The mean physical function score and mental health score significantly increased by 15% (p = .009) and 28% (p < .001), respectively.

Conclusion

Our findings showed dienogest treatment at oral doses of 2 mg/day for 3 months significantly reducing the size of endometrioma, reducing pain level, and increasing quality of life in women with endometriosis.

摘要

目的：研究地诺孕素对子宫内膜异位症患者的囊肿体积、症状和生活质量的影响。

方法：这项前瞻性队列研究包括37名诊断为子宫内膜异位症并计划进行药物治疗的患者。受试者予口服地诺孕素2 mg/天进行3个月治疗。通过三维超声评估测量治疗前后子宫内膜异位病灶, 通过视觉模拟量表（VAS）评估疼痛症状, 应用生活质量评价量表SF-36评估生活质量。

结果：患者的平均年龄为36.0±6.6岁。患者的子宫内膜异位囊肿的平均体积与治疗前相比（26.7 ± 19.7 mm3）, 治疗后平均体积明显减少31% (17.4 ± 11.2 mm3, p＜.001)。治疗后痛经、排尿困难和慢性盆腔疼痛的VAS评分显著下降, 分别降低了35.5%（p＜.001）、37.5%（p＜.001）和38.5%（p＜.001）。平均生理功能评分和精神健康评分显著增加分别为15% (p =.009)和28% (p＜.001)。

结论：本研究结果显示口服地诺孕素2mg/天治疗3个月, 可显著减少子宫内膜异位病灶大小, 降低疼痛程度, 并提高子宫内膜异位症女性的生活质量。

Keywords:

• Dienogest
• endometriosis
• endometrioma
• pain
• quality of life

Acknowledgments

Approval was obtained by the institutional review board from Ankara Etlik Zubeyde Hanım Women’s Health Training and Research Hospital on November 18 2020 # 2020/159.

Informed consent

A verbal and written informed consent was obtained from all participants.

Disclosure statement

The authors declare no conflicts of interest.

Data availability statement

Data are openly available in a public repository that issues data sets with DOIs.

Author contribution

All of the authors, YK, MCI, SKA, YEU have contributed to the project development, data collection, data analysis, and writing of the manuscript.

Additional information

Funding

The study did not receive funding.